SequelSEC

Sana Biotechnology, Inc. SANA

Biological Products, (No Diagnostic Substances) · CIK 0001770121 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$250.32M
Fiscal year ended 2025-12-31
Free cash flow
-$144.77M
Fiscal year ended 2025-12-31

Sana Biotechnology, Inc. (SANA) reported net income of -$244.17M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Sana Biotechnology, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Sana Biotechnology, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$250.32M-$272.72M-$293.14M-$272.56M-$356.91M-$286.15M-$141.15M
Net income-$244.17M-$266.76M-$283.26M-$269.48M-$355.93M-$285.30M-$130.78M
Research & development$131.98M$215.67M$261.81M$285.88M$248.63M$132.94M$99.59M
Weighted-average diluted sharesshares 253.23Mshares 230.89Mshares 194.54Mshares 188.34Mshares 166.43Mshares 13.01MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailable-$355.93M-$285.30M-$138.32M
Income tax expense$0UnavailableUnavailableUnavailableUnavailableUnavailable-$7.55M
Diluted EPS$-0.96$-1.16$-1.46$-1.43$-2.14$-21.92Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$44.30M$64.04M$73.30M$71.56M$50.41M$28.27M$21.78M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Sana Biotechnology, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$71.87M$127.57M$133.52M$176.76M$253.03M$124.81MUnavailable
Total assets$416.89M$501.02M$565.30M$822.72M$1.13B$730.30MUnavailable
Current assets$148.68M$160.81M$213.52M$444.44M$558.10M$384.47MUnavailable
Total liabilities$256.01M$250.52M$277.79M$323.40M$400.90M$298.58MUnavailable
Current liabilities$78.73M$45.43M$64.49M$111.50M$99.24M$31.45MUnavailable
Total equity incl. NCI$160.88M$250.50M$287.51M$499.32M$728.50M-$421.18M-$142.54M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailable$852.90MUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Goodwill$140.63M$140.63M$140.63M$140.63M$140.63M$140.63MUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.67M$5.21M$4.11M$2.86M$2.22M$2.25MUnavailable

Cash flow

Sana Biotechnology, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$143.83M-$223.15M-$253.58M-$290.05M-$251.05M-$137.98M-$85.52M
Capital expenditures$938.00K$33.43M$20.03M$20.88M$29.86M$23.87M$26.12M
Investing cash flow-$40.24M$17.45M$172.01M$210.56M-$245.80M-$252.56M-$87.86M
Financing cash flow$128.73M$199.75M$31.65M$4.91M$631.75M$435.69M$223.74M
Net change in cash-$55.33M-$5.95M-$49.92M-$74.58M$134.90M$45.14M$50.36M
Stock-based compensation$25.46M$37.68M$35.53M$38.34M$22.36M$5.83M$1.50M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Sana Biotechnology, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flow-$144.77M-$256.58M-$273.61M-$310.93M-$280.92M-$161.85M-$111.64M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio1.89x3.54x3.31x3.99x5.62x12.22xUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SANA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-03View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.